Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 10Phase 1 5Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 19Solid Tumor 18Breast Neoplasms 14Sarcoma 13Head and Neck Neoplasms 13Colorectal Neoplasms 13Neoplasms 12Lymphoma, B-Cell 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Melanoma 10Lymphoma 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Prostatic Neoplasms 7Leukemia 7Burkitt Lymphoma 7Advanced Solid Tumors 7Ovarian Neoplasms 6Hematologic Neoplasms 6Glioblastoma 6Recurrence 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Cachexia × Clear all
NCT06736275 2026-05-15

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Jiangsu Nutai Biologics Co., Ltd

Phase EARLY_PHASE1 Recruiting
28 enrolled

Cachexia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡